Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 20/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 20/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 20/20 | 0.71 |
| ▸ | ADRA1D | P25100 | 14/20 | 0.71 |
| ▸ | ADRA1B | P35368 | 12/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brimonidine SCHEMBL29374525 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL29171467 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL7028091 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL24670 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL20511531 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL3346716 | 0.83 | ADRA2A (0.63) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL1685506 | 0.82 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL22616115 | 0.82 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL252912 | 0.79 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL3346324 | 0.79 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012001065-A2 | METHOD FOR PREVENTING OR TREATING SKIN TUMOR | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | disclosed |
| US-20110060045-A1 | ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2011-03-10 | — | — | US | disclosed |
| US-7858560-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| EP-1549305-B1 | ALPHA 2B 0R 2B/2C ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF MORBUS ALZHEIMER AND MORBUS PARKINSON | ALLERGAN INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1485707-B1 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | CAPROTEC BIOANALYTICS GMBH (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060045-A1 | ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES | INSR, GPR119, ADRB1 | ADRA2A 43/4885ADRA2B 39/4885ADRA2C 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.